Please login to the form below

Not currently logged in

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis


Pfizer and Roivant Sciences have launched a new company focused on developing RVT-3101, a fully human monoclonal antibody targeting TL1A, for inflammatory and fibrotic diseases.

RVT-3101, which was originally developed by Pfizer, targets both inflammatory and fibrotic pathways by inhibiting TL1A, which has been shown to modulate the location and severity of inflammation and fibrosis.

The candidate has already been evaluated in an earlier phase 2 study – TUSCANY – in 50 patients, and is currently being evaluated in a large global phase 2b study – TUSCANY-2 – in 245 adult participants with moderate-to-severe ulcerative colitis (UC).

The new company, which has been created to develop these programmes, will be fully responsible for funding global development of RVT-3101 in UC and in additional inflammatory and fibrotic diseases and holds commercial rights in the US and Japan.

Pfizer, which will hold a 25% stake in the new business, will maintain commercial rights outside of the US and Japan.

“Our internally discovered antibody against TL1A, could potentially be the first agent to bring biomarker-selected precision medicine to people living with inflammatory bowel disease,” said Mikael Dolsten, Pfizer’s chief scientific officer, president, worldwide research, development and medical.

The new unit also has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered phase 1.

Inflammatory bowel diseases, including UC and Crohn’s disease, affect around two million adults in the US. High rates of treatment failure mean that approximately 50% of patients are cycling off a given therapy within six to 12 months and are unlikely to achieve sustained remission, underscoring the need for new efficacious treatment options.

Mayukh Sukhatme, president and chief investment officer of Roivant, said: “We believe in RVT-3101’s potential to transform the inflammatory bowel disease landscape, which has long been in need of new, innovative therapies with greater efficacy.

“... TUSCANY-2 builds on the earlier TUSCANY data with many firsts for the class – TUSCANY-2 is the first study with subcutaneous efficacy data and the first dose-ranging study – and is among the largest phase 2b studies ever conducted in the indication. We are encouraged by the preliminary data and look forward to presenting the data and to seeing other results from the class.”

Article by
Emily Kimber

5th December 2022

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...